Dr. Marina Chiara Garassino is the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milan, Italy. She leads the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma and thymic malignancies. Istituto Nazionale dei Tumori in Milan is the most important Comprehensive Cancer Center in Italy, and one of the most important in Europe. As a medical oncologist, she has done research in precision medicine and in immuno-oncology. Her main research interests have been: NSCLC, SCLC, mesothelioma and development of biomarkers. She has contributed to over 160 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology. She has delivered many presentations at international congresses, including AACR, ASCO, ECCO, ESMO, WCLC. Her education includes a degree and further specialization in Medical Oncology at Università degli Studi, in Milan. She completed her training with an ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). She was a member of the EMA SAG (Scientific Advisory Group). She achieved a Master Degree in Oncology management at University of Economics “Luigi Bocconi”. Dr Garassino is serving on several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology Committee, Lung Cancer faculty, Membership Committee) and as Chair of the National Societies Committee, from 2019. She is the founder and president of Women for Oncology Italy.
Dr. Randeep Sangha is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada. Dr Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies. Dr Sangha has been the provincial lead for the Alberta Lung Cancer Tumor Team (2013 - 2020). His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics
For more information, please send requests to Robyn Leonard at email@example.com.